PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Can J Anaesth. Author manuscript; available in PMC 2010 May 27.
Published in final edited form as:
PMCID: PMC2877586
NIHMSID: NIHMS199401

Natural Inhibitors of Cholinesterases: Implications for Adverse Drug Reactions

Abstract

Purpose

Acetylcholinesterase and butyrylcholinesterase are two closely related enzymes important in the metabolism of acetylcholine and anaesthetic drugs, including succinylcholine, mivacurium, and cocaine. The solanaceous glycoalkaloids (SGAs) are naturally occurring steroids in potatoes and related plants that inhibit both acetylcholinesterase and butyrylcholinesterase. There are many clinical examples of direct SGA toxicity due to cholinesterase inhibition. The aim of this study was to review the hypotheses that (1) SGAs may be the evolutionary driving force for atypical butyrylcholinesterase alleles and that (2) SGAs may adversely influence the actions of anaesthetic drugs that metabolized by acetylcholinesterase and butyrylcholinesterase.

Source

The information was obtained by Medline search and consultation with experts in the study of SGAs and cholinesterases.

Principal findings

The SGAs inhibit both acetylcholinesterase and butyrylcholinesterase in numerous in vitro and in vivo experiments. Although accurate assays of SGA levels are difficult, published data indicate human serum SGA concentrations at least ten-fold lower than required to inhibit acetylcholinesterase and butyrylcholinesterase in vitro. However, we review evidence that suggests the dietary ingestion of SGAs can initiate a cholinergic syndrome in humans. This syndrome occurs at SGA levels lower than those which interfere with anaesthetic drug catabolism. The world distribution of solanaceous plants parallels the distribution of atypical alleles of butyrylcholinesterase and may explain the genetic diversity of the butyrylcholinesterase gene.

Conclusion

Correlative evidence suggests that dietary SGAs may be the driving force for atypical butyrylcholinesterase alleles. In addition, SGAs may influence the metabolism of anaesthetic drugs and this hypothesis warrants experimental investigation.

INTRODUCTION

Acetylcholinesterase (AChE; E.C. 3.1.1.7) and butyrylcholinesterase (BuChE; acylcholine acylhydrolase; pseudocholinesterase; E.C. 3.1.1.8) are two closely related enzymes found in all vertebrate species. Acetylcholinesterase is vital to mammalian life, playing a crucial role in the neuromuscular junction by terminating cholinergic transmission. It is also a target for numerous inhibitors, such as neostigmine, which are important in medical therapy and toxicology. In contrast to AChE, the normal physiological function of BuChE remains a matter of speculation.1 Of clinical importance to anaesthetists, BuChE hydrolyzes and limits the duration of the neuromuscular blocking agents succinylcholine and mivacurium, as well as ester local anaesthetics. Butyrylcholinesterase also hydrolyzes other compounds such as cocaine2 and heroin.3 Individuals who possess certain variant alleles for BuChE hydrolyze succinylcholine and mivacurium very slowly and develop prolonged apnea when these agents are used during anaesthesia.47 Awareness of this untoward effect of succinylcholine led to the development of the dibucaine number assay, which predicts the presence of atypical BuChE alleles from differential inhibition of BuChE by the ester local anaesthetic dibucaine.8

The growing awareness of the role of BuChE in drug metabolism has led to interest in factors that alter its activity. A non-genetic factor that may influence BuChE activity is liver failure since BuChE is synthesized in the liver; in severe cases of hepatic dysfunction, response to succinylcholine can be prolonged.9 Another clinically important drug interaction is that pancuronium and other myorelaxants inhibit BuChE, thus prolonging the action of drugs, such as mivacurium, dependent on BuChE-dependent catabolism (Figure 1).10

FIGURE 1
Spontaneous electromyography recovery of neuromuscular block after 10 (triangles) or 70 (circles), μg·kg−1 mivacurium given at T1 35% during recovery from pancuronium (closed symbols) or mivacurium (open symbols). Groups differed ...

Depression in BuChE activity also appears to mediate adverse drug reactions to drugs other than the neuromuscular antagonists. For example, cocaine users who are suffering life-threatening adverse reactions have lower plasma BuChE concentrations than cocaine users presenting with less severe toxicity. There is also the suggestion that BuChE limits the adverse effects of maternal cocaine use on fetal development.11 The human term placenta expresses BuChE, and the level and type of BuChE expression may be crucial in reducing fetal exposure to cocaine.12

Separate genes encode AChE and BuChE enzymes. In humans, the gene for AChE is located on chromosome 7, while the gene for BuChE is located on chromosome 3.1316 Although the DNA sequences for the AChE and BuChE genes differ considerably (i.e., the A, C, G, T sequences are different), the amino acid sequences of the enzymes encoded by the genes are >50% homologous. In addition, the BuChE and AChE genes share a similar intron-exon organization, i.e., the length, placement, and number of exons and introns comprising these genes are similar. The similarities of these genes implies that they arose from a common ancestral cholinesterase gene.

The evolution of proteins can also be inferred by comparison of DNA sequences of genes in different species. For the cholinesterases, the electric eel expresses two distinct cholinesterases (BuChE and AChE), while insects produce a single enzyme with AChE/BuChE properties.17,18 It is theorized that primitive life first developed a single cholinesterase gene and protein that duplicated into two copies and, over time, mutated into two separate genes encoding different enzymes. Since all vertebrates contain two distinct cholinesterases, it is presumed that distinct BuChE and AChE genes and proteins actually evolved before the appearance of the first vertebrates.19

Genetic variation of the BuChE gene has been extensively explored.20 More than 20 different naturally occurring BuChE mutants exist; some of these possess substantially different functional and pharmacological properties.21 The most common of these is a point mutation that substitutes glycine for aspartate at position 70 (D70G), resulting in the so-called “atypical” allele.6 The extensive variation of the gene for BuChE suggests a driving force and selective advantage for such variation.22 Of possible importance in this regard is that natural compounds found in potatoes and related plants inhibit both AChE and BuChE. Many of the BuChE allelic variants display different sensitivities to these natural inhibitors, and this may confer an evolutionary advantage against toxic dietary exposure.

A number of naturally occurring BuChE and AChE inhibitors have been discovered, including solanaceous glycoalkaloids (SGAs), organophosphates from cyanobacteria,23 and the fungal antibiotics puromycin and related analogs.24 The most common naturally occurring cholinesterase inhibitors, the SGAs, are found in plants of Solanaceae such as potato, eggplant, and tomato. The main SGAs in potatoes are α-solanine and α-chaconine, both triglycosides of solanidine, a steroidal alkaloid derived from cholesterol (Figure 2). Solanaceous glycoalkaloids have elicited concern about toxicity since among 5,000–10,000 identified plant toxins they alone inhibit both AChE and BuChE.25 This review summarizes the effects of SGAs in humans and animals. The other natural inhibitors of AChE and BuChE are not considered since they have been less well studied.

FIGURE 2
Molecular structures of the solanaceous glycoalkaloids α-solanine and α-chaconine. The steroidal backbone without the attached sugar moieties is the compound solanidine.

Awareness of the action of SGAs on BuChE may be important for three reasons. First, depression of BuChE activity has implications for the use of anaesthetics and other drugs, since SGA depression of BuChE activity may influence drug toxicity. Second, inhibition of esterases is important not only with established drugs, such as succinylcholine and mivacurium, but also with newer drugs, such as remifentanil, that are hydrolyzed by non-specific esterases.26,27 Medicinal chemists have increasingly designed drugs that capitalized on enzymatic breakdown to insure reliable termination of action. The implicit assumption in this strategy is that degradatory capacity is increased by the sensitivity of the drug to these non-specific esterases, and thus the influence of inhibitors of AChE and BuChE is minimized. Although no important interactions of AChE and BuChE inhibitors with remifentanil have yet been reported, and hepatic failure affects catabolism minimally,28 the action of solanidine on nonspecific esterases has not been investigated. Given the trend to develop drugs with rapid catabolism by esterases, it is increasingly important to recognize and test for genetic and environmental influences that might alter the pharmacokinetic behavior of such drugs. Third, the presence and evolutionary influence of natural BuChE inhibitors such as the SGAs may help to explain the extensive genetic variation for the BuChE gene. In particular, differential sensitivity to natural inhibitors by BuChE variants may provide an evolutionary selective advantage.

Solanaceous glycoalkaloid levels vary considerably among different plant species and vary with light exposure, mechanical damage, and the vegetable or fruit part (e.g., skin, tuber, green sprouts) (Table I). In potatoes, green shoots or skin often considerably higher levels of SGAs than other parts of the plant. Higher levels of SGAs generally impart a bitter, unpleasant taste.29 Exposure to light, mechanical damage, and spoiling increases SGA levels; cooking does not alter levels.30

Table I
Glycoalkaloid Content of Various Food Products

Solanaceous glycoalkaloids received scrutiny as a result of documented outbreaks of toxicity in humans and livestock after potato consumption. The long history of potato toxicity31,32 includes some fatalities.33 The clinical symptoms of potato toxicity in humans are fairly consistent throughout documented cases: acute gastrointestinal disturbances (abdominal pain, vomiting, and diarrhoea) progressing in severe cases to profound neurological symptoms (apathy, drowsiness, mental confusion, stupor, visual disturbances, dizziness, hallucinations, and trembling). Many of these symptoms mimic the clinical syndrome of massive cholinergic stimulation. Symptoms last approximately 2–24 hr after ingestion of potatoes.31 The most recent major outbreak involved 78 British schoolchildren in which the most severely affected child recovered only after one week of hospitalization. Butyrylcholinesterase concentrations in 10 to 17 children analyzed were abnormally low six days after exposure. In all but one case, levels had returned to normal after four to five weeks.34 This analysis suggests a substantial reservoir of SGAs after consumption of potatoes.

In addition to the clinical reports demonstrating toxic effects similar to those following inhibition of AChE, there are numerous animal and human experiments suggesting that normal nutritional intake of these natural inhibitors may result in levels that inhibit AChE and/or BuChE. This may then create direct toxic effect or, more insidiously, cause altered metabolism of compounds metabolized by BuChE. Morris and Lee32 concluded that 2–5 mg SGA·kg−1 body weight (BW) is toxic and that 3–6 mg·kg−1 BW is potentially fatal. Subsequent research has supported this estimate and some investigators suggest that the toxic dose may be as low as 1 mg·kg−1 BW. For example, in three studies using male volunteers, symptoms of diarrhea, vomiting, and/or nausea occurred at SGA levels of 1.0–2.6 mg·kg−1 BW.35 The daily average amount of potatoes consumed by individuals in the United States, Great Britain, and Sweden is 167 g,36 140 g,37 and 300 g,38 respectively. Current agricultural guidelines recommend that potatoes for consumption contain no more than 200 mg·kg−1 SGA (Friedman M and MacDonald GM, Potato glycoalkaloids: chemistry, analysis, safety, and plant physiology. Critical Rev. Plant Sciences, in press). Many potato products contain SGA levels close to this concentration (Table I). Individuals consuming a standard serving of potatoes can ingest as much as 20 to 60 mg SGA. This amount overlaps the potentially toxic range of SGA in small children and heavier consumption of foods containing SGAs would also reach the toxic range in adults. Although severe direct toxicity caused by SGAs is rare, the possibility that SGAs under typical dietary conditions may alter BuChE-mediated metabolism has not been addressed experimentally. Given the wide range of commonly used drugs that appear to depend on BuChE for proper termination of action, the effects of SGA inhibition warrant careful study.

Animal studies also illustrate the toxicity of SGAs; however, no animal appears to be as sensitive to SGAs as humans. The oral lethal dose in sheep is 500 mg·kg−1 BW with toxic effects noted at 225 mg·kg−1 BW.39 Rabbits fed greened potatoes (64 mg SGA per day) for 30 days showed a greater rate of death and weight loss than rabbits fed normal potatoes (22 mg SGA per day).40 Administered orally, SGAs show poor bioavailability in rats and mice.41,42 In fact, oral administration must exceed 1000 mg·kg−1 BW to produce toxic effects in mice. In contrast, parenteral administration of solanine at concentrations as low as 1–20 mg·kg−1 BW is very toxic to mice, rats, and rabbits.41 Hamsters seem to have a sensitivity to SGAs closest to that of humans. For this reason, some investigators suggest that hamsters are the preferred animal model for studying the toxic effects of SGAs (Friedman and MacDonald, in press).

Solanaceous glycoalkaloids inhibit both BuChE and AChE in in vitro and in vivo studies (see below). Since symptoms of potato and SGA toxicity resemble the syndrome of massive cholinergic stimulation, inhibition of AChE at cholinergic synapses probably accounts for most of the direct toxic effects of SGAs described above. Pokrovskii first demonstrated anti-cholinesterase activity in potato extracts,43 and other investigators subsequently confirmed the finding.4446 Table II and Figures 3 and and44 summarize the results the results of in vitro studies that have quantified inhibition of BuChE and AChE by SGAs. Clearly, the reported levels of inhibition vary considerably. However, SGAs, in sufficiently high concentrations, inhibit both BuChE and AChE in vitro as effectively as neostigmine.

FIGURE 3
Solanaceous glycoalkaloids and dibucaine inhibit butyrylcholinesterase. The atypical butyrylcholinesterase enzyme is much less sensitive to this inhibition. Semi-log plots showing the effects the ester anaesthetic dibucaine (A) and the solanaceous glycoalkaloids ...
FIGURE 4
Solanaceous glycoalkaloids inhibit acetycholinesterase. Semi-log plot showing the effect of the solanaceous glycoalkaloids α-solanine (closed circles) and α-chaconine (open circles) on inhibition of bovine acetylcholinesterase at pH 7. ...
Table II
Summary of In Vitro Studies That Assess Cholinesterase Inhibition by Solanaceous Glycoalkaloids

In animals given SGAs, AChE inhibition has not been established definitively. Rabbits given 20 mg·kg−1 BW solanine intraperitoneally died within 24 hr. Plasma BuChE and erythrocyte AChE inhibition ranged from 55.5% to 88.2% of control, with some animals showing inhibition up to four hours after dose.47 Mice fed 1000–2000 mg·kg−1 BW SGAs from Solanum dimidiatum (a wild plant known as potatoweed which appears to cause a neurological condition known as “crazy cow syndrome” in grazing cattle experienced a statistically significant (30%) inhibition of AChE (Hueske KL. The neurological effects of Solanum dimidiatum in mice, PhD Dissertation. Texas A & M University, 1991).

In humans, SGAs are sequestered in the body for long periods and may have long-term effects on BuChE and AChE activity. In one study, <10% of orally administered 3H-labeled solanidine was excreted in 24 hr.48 The advent of sensitive radioimmunoassay (RIA)49 and high-performance liquid chromatography (HPLC)35 techniques for quantifying SGA concentrations in human blood serum have provided additional support for accumulation of detectable levels of SGA from a normal diet. Radioimmunoassay methods have detected total potato SGA blood serum concentrations of 3.2–125 nM and 2.5–92.5 nM in healthy subjects from the United Kingdom and Sweden, respectively.50,51 In another study, subjects who had eaten a meal of potatoes tailored to provide a load of 1 mg SGA mg·kg−1 BW, exhibited serum levels of α-solanine from 4.5–12.9 nM and of α-chaconine from 7.3–25.1 nM, as assessed by HPLC. The alkaloid levels peaked at four to six hours, and then decreased with a mean t1/2 of 11 and 19 hr, respectively.35 Dosing may also be important with SGAs. Larger single doses are more toxic than a series of smaller doses in animals, even when the total amount delivered by smaller dosing is much greater.52 Oral absorption of SGAs increases with the size of individual doses.41,42 The data above suggest that SGAs may be stored in the body for extended periods. Thus, chronic SGA consumption may result in a considerable SGA pool.

The key question for clinicians is whether normal dietary consumption of solanaceous plants can result in concentrations of SGAs that produce clinically important effects. Although accurate measurement of SGAs is difficult and different methods often provide conflicting results (Friedman and MacDonald), the weight of evidence suggests plasma SGA levels associated with normal animal dietary consumption may be lower than those required to inhibit AChE and BuChE in vitro. The pharmacokinetic studies above demonstrate submicromolar concentrations of SGAs in human plasma. However, only two in vitro studies cited in Table II tested the effects of submicromolar SGA concentrations. In one of these,53 100 nMα-solanine and α-chaconine failed to inhibit bovine AChE; in the other, however, 100 nM α-chaconine inhibited human recombinant BuChE by approximately 15%.22 Thus, considerable inhibition of BuChE by nanomolar concentrations of SGAs may occur in humans.

Even though α-solanine and α-chaconine are the major SGAs in potatoes and related plants, other alkaloids exist in the same food products. How the SGAs interact with each other is unknown. Some experiments have described synergistic effects in the toxic actions of SGAs.52 Although no synergy was observed in one study assessing inhibition of AChE in vitro,53 the complex mixture of SGAs found in potatoes and other plants suggests that synergistic interaction is possible. The potential inhibition of cholinesterase activity by extracts of potatoes (Table II) may indicate synergistic effects.

The effects of SGAs on BuChE may be a rationale for the persistence of certain atypical BuChE alleles for thousands of years.54 The sera of individuals who are dibucaine “resistant” (i.e., they are homozygous for the “atypical” BuChE allele) show markedly lower degrees of cholinesterase inhibition after in vitro application of approximately 3 μM solanine and solanidine.45 Recombinant atypical BuChE is also resistant to SGA inhibition (Figure 3).55 Variant BuChE alleles may confer a selective evolutionary advantage against exposure to natural glycoalkaloids.22,55 An association between cultivation of the Solanum eggplant (S. melongema) and a high frequency of variant BuChE alleles in certain Middle Eastern ethnic groups has been proposed as one possible evolutionary advantage for BuChE genetic variation (Figure 5).54 In addition, many ancestral species of the modern commercial potato have extremely high SGA levels (some greater than 1000 mg ·kg−1), and among them, three wild species are known to have been consumed throughout history.56 The potato appears to have been first cultivated in the Andes and was transported to Europe beginning in the 16th century.57 Atypical BuChE alleles occur with high frequency in the Americas, Europe, and some Middle East regions, with very low frequency in Africa and Asia (Figure 5).20 This fact is consistent with the hypothesis that SGAs may be a driving force for the persistence of the mutant BuChE allele.

FIGURE 5
World map showing the frequency of the allele for the atypical butyrylcholinesterase in different regions. The numbers indicate number of atypical genes per thousand. Note the especially high frequency of the atypical allele in South and Central America, ...

The above hypothesis depends upon vital physiological function for BuChE. Although crucial physiological roles of BuChE are not clear, recent research suggests an important role in cellular growth and development. For example, the BuChE gene is intensively expressed in bone marrow cells58 and fetal tissue.59 In addition, the gene is amplified during haematopoiesis60 and in ovarian carcinomas.61 Also, its expression may be induced by exposure to certain toxins. For example, prolonged exposure of a family to organophosphate insecticides was shown to result in an abnormally high number of copies of the BuChE gene in germ cells (i.e., sperm or eggs).62 In addition to the most common mutation of BuChE, which occurs at approximately 1:3500 in the population, there are mutations in BuChE that occur naturally which lack enzymatic activity entirely. Individuals who are homozygous for such mutant alleles, while rare (0.001% of homozygotes),6,20 appear to be phenotypically normal. Although this argues against a critical role for BuChE, compensatory mechanisms may operate in these rare individuals who completely lack catalytically active BuChE. Also, the effect of acute exposure to natural BuChE inhibitors at crucial periods of development may be harmful due to the insufficient activation of protective mechanisms.21

Conclusion

Experimental evidence reveals that SGAs are able to inhibit AChE and BuChE both in vivo and in vitro. The documented cases of direct SGA toxicity resemble massive cholinergic stimulation as a result of AChE inhibition. The inhibition of BuChE may influence its reported role in growth and development. The origins of plants containing high SGA levels parallels the world distribution of the atypical BuChE allele, which is much less sensitive to SGA inhibition. Consequently, it is reasonable to hypothesize that resistance to SGA inhibition has been an evolutionary driving force for the high frequency of atypical alleles in some areas of the world.

It is not clear whether the SGAs may influence the pharmacokinetic behaviour of drugs dependent on BuChE for catabolism. There has recently been an increased appreciation that dietary intake can influence pharmacokinetics and drug disposition and metabolism. For instance, grapefruit juice markedly inhibits first-pass metabolism of many drugs, including felodipine and nifedipine.63 The clinical syndromes of potato toxicity under a variety of conditions in humans and animals strongly suggests that SGAs from potatoes inhibit AChE and BuChE. In vitro data indicate that SGAs inhibit BuChE at least as potently as AChE. Thus it is reasonable to hypothesize that SGAs may alter the pharmacokinetics of drugs metabolized by BuChE, although conclusive experimental evidence on this is currently lacking.

Acknowledgments

Peter Sporns, PhD, Mendel Friedman, PhD, and Rodney J. Bushway, PhD for helpful discussions and unpublished observations. MDK received support from National Institutes of Health grant MH11504.

References

1. Cooper JR. Unsolved problems in the cholinergic nervous system. J Neurochem. 1994;63:395–9. [PubMed]
2. Stewart DJ, Inaba T, Tang BK, Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 1977;20:1557–63. [PubMed]
3. Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp Ther. 1980;215:1–8. [PubMed]
4. Cook DR, Stiller RL, Weakly JN, Chakravorti S, Brandom BW, Welch RM. In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine. Anesth Analg. 1989;68:452–6. [PubMed]
5. Hodgkin W, Giblett ER, Levine H, Bauer W, Motulsky AG. Complete Pseudocholinesterase Deficiency: Genetic And Immunologic Characterization. J Clin Invest. 1965;44:486–93. [PMC free article] [PubMed]
6. McGuire MC, Nogueira CP, Bartels CF, et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc Natl Acad Sci U S A. 1989;86:953–7. [PubMed]
7. Petersen RS, Bailey PL, Kalameghan R, Ashwood ER. Prolonged neuromuscular block after mivacurium. Anesth Analg. 1993;76:194–6. [PubMed]
8. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol. 1957;35:339–46. [PubMed]
9. Viby-Mogensen J, Hanel HK. Prolonged apnoea after suxamethonium: an analysis of the first 225 cases reported to the Danish Cholinesterase Research Unit. Acta Anaesthesiol Scand. 1978;22:371–80. [PubMed]
10. Erkola O, Rautoma P, Meretoja OA. Mivacurium when preceded by pancuronium becomes a long-acting muscle relaxant. Anesthesiology. 1996;84:562–5. [PubMed]
11. Konkol RJ, Murphey LJ, Ferriero DM, Dempsey DA, Olsen GD. Cocaine metabolites in the neonate: potential for toxicity. J Child Neurol. 1994;9:242–8. [PubMed]
12. Simone C, Derewlany LO, Oskamp M, Johnson D, Knie B, Koren G. Acetylcholinesterase and butyrylcholinesterase activity in the human term placenta: implications for fetal cocaine exposure. J Lab Clin Med. 1994;123:400–6. [PubMed]
13. Allderdice PW, Gardner HA, Galutira D, Lockridge O, LaDu BN, McAlpine PJ. The cloned butyrylcholinesterase (BCHE) gene maps to a single chromosome site, 3q26. Genomics. 1991;11:452–4. [PubMed]
14. Ehrlich G, Viegas-Pequignot E, Ginzberg D, Sindel L, Soreq H, Zakut H. Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries. Genomics. 1992;13:1192–7. [PubMed]
15. Getman DK, Eubanks JH, Camp S, Evans GA, Taylor P. The human gene encoding acetylcholinesterase is located on the long arm of chromosome 7. Am J Hum Genet. 1992;51:170–7. [PubMed]
16. Gnatt A, Prody CA, Zamir R, Lieman-Hurwitz J, Zakut H, Soreq H. Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors. Cancer Res. 1990;50:1983–7. [PubMed]
17. Hall LM, Malcolm CA. The acetylcholinesterase gene of Anopheles stephensi. Cell Mol Neurobiol. 1991;11:131–41. [PubMed]
18. Toutant JP, Massoulie J, Bon S. Polymorphism of pseudocholinesterase in Torpedo marmorata tissues: comparative study of the catalytic and molecular properties of this enzyme with acetylcholinesterase. J Neurochem. 1985;44:580–92. [PubMed]
19. Taylor P. The cholinesterases. J Biol Chem. 1991;266:4025–8. [PubMed]
20. Whittaker M. Cholinesterase. In: Beckman L, editor. Monographs in Human Genetics. Basel: Karger; 1986. pp. 45–85.
21. Schwarz M, Glick D, Loewenstein Y, Soreq H. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. Pharmacol Ther. 1995;67:283–322. [PubMed]
22. Neville LF, Gnatt A, Loewenstein Y, Seidman S, Ehrlich G, Soreq H. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. Embo J. 1992;11:1641–9. [PubMed]
23. Carmichael WW. The toxins of cyanobacteria. Sci Am. 1994;270:78–86. [PubMed]
24. Hersh LB. Inhibition of aminopeptidase and acetylcholinesterase by puromycin and puromycin analogs. J Neurochem. 1981;36:1594–6. [PubMed]
25. Ames BN, Profet M, Gold LS. Dietary pesticides (99.99% all natural) Proc Natl Acad Sci U S A. 1990;87:7777–81. [PubMed]
26. Feldman PL, James MK, Brackeen MF, et al. Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics. J Med Chem. 1991;34:2202–8. [PubMed]
27. Glass PS, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B) Anesth Analg. 1993;77:1031–40. [PubMed]
28. Dershwitz M, Hoke JF, Rosow CE, et al. Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease. Anesthesiology. 1996;84:812–20. [PubMed]
29. Sinden SL, Deahl KL, Aulenbach B. Effect of glycoalkaloids and phenolics on potato flavor. J Food Sci. 1976;41:520–3.
30. Bushway RJ, Bureau JL, McGann DF. Alpha-chaconine and alpha-solanine content of potato peels and potato peel products. J Food Sci. 1983;48:84–6.
31. Harris FW, Cockburn T. Alleged poisoning by potatoes. Analyst. 1918;43:133–7.
32. Morris SC, Lee TH. The toxicity and teratogenicity of Solanaceae glycoalkaloids, particularly those of the potato (Solanum tuberosum): a review. Food Technol Austral. 1984;36:118–24.
33. Hansen A. Two fatal cases of potato poisoning. Science. 1925;61:340–1. [PubMed]
34. McMillan M, Thompson JC. An outbreak of suspected solanine poisoning in schoolboys: Examinations of criteria of solanine poisoning. Q J Med. 1979;48:227–43. [PubMed]
35. Hellenas KE, Nyman A, Slanina P, Loof L, Gabrielsson J. Determination of potato glycoalkaloids and their aglycone in blood serum by high-performance liquid chromatography. Application to pharmacokinetic studies in humans. J Chromatogr. 1992;573:69–78. [PubMed]
36. Willard M. Potato processing: past, present, and future. Am Potato J. 1993;70:405–18.
37. Hopkins J. The glycoalkaloids: naturally of interest (but a hot potato?) Food Chem Toxicol. 1995;33:323–8. [PubMed]
38. Slanina P. Solanine (glycoalkaloids) in potatoes: toxicological evaluation. Food Chem Toxicol. 1990;28:759–61. [PubMed]
39. Jadhav SJ, Sharma RP, Salunkhe DK. Naturally occurring toxic alkaloids in foods. Crit Rev Toxicol. 1981;9:21–104. [PubMed]
40. Azim A, Shaikh HA, Ahmad R. Effect of feeding greened potatoes on different visceral organs and blood plasma of rabbits. J Sci Food Agric. 1982;33:1275–9. [PubMed]
41. Nishie K, Gumbmann MR, Keyl AC. Pharmacology of solanine. Toxicol Appl Pharmacol. 1971;19:81–92. [PubMed]
42. Norred WP, Nishie K, Osman SF. Excretion, distribution and metabolic fate of 3H-alpha-chaconine. Res Commun Chem Pathol Pharmacol. 1976;13:161–71. [PubMed]
43. Povrovskii A. The effects of the alkaloids of the sprouting potato on cholinesterase [Russian] Biokhimiia. 1956;21:705–10.
44. Harris H, Whittaker M. Differential response of human serum cholinesterase types to an inhibitor in potato. Nature. 1959;183:1808–9. [PubMed]
45. Harris M, Whittaker M. Differential inhibition of the serum cholinesterase phenotypes by solanine and solanidine. Ann Hum Genet. 1962;26:73–6. [PubMed]
46. Orgell WH, Vaidya KA, Dahm PA. Inhibition of human plasma cholinesterase in vitro by extracts of solanaceous plants. Science. 1958;128:1136–7. [PubMed]
47. Patil BC, Sharma RP, Salunkhe DK, Salunkhe K. Evaluation of solanine toxicity. Food Cosmet Toxicol. 1972;10:395–8. [PubMed]
48. Claringbold WD, Few JD, Renwick JH. Kinetics and retention of solanidine in man. Xenobiotica. 1982;12:293–302. [PubMed]
49. Matthew JA, Morgan MR, McNerney R, Chan HW, Coxon DT. Determination of solanidine in human plasma by radioimmunoassay. Food Chem Toxicol. 1983;21:637–40. [PubMed]
50. Harvey MH, McMillan M, Morgan MR, Chan HW. Solanidine is present in sera of healthy individuals and in amounts dependent on their dietary potato consumption. Hum Toxicol. 1985;4:187–94. [PubMed]
51. Harvey MH, Morris BA, McMillan M, Marks V. Measurement of potato steroidal alkaloids in human serum and saliva by radioimmunoassay. Hum Toxicol. 1985;4:503–12. [PubMed]
52. Swinyard CA, Chaube S. Are potatoes teratogenic for experimental animals? Teratology. 1973;8:349–57. [PubMed]
53. Roddick JG. The acetylcholinesterase-inhibitory activity of steroidal glycoalkaloids and their aglycones. Phytochemistry. 1989;28:2631–4.
54. Ehrlich G, Ginzberg D, Loewenstein Y, et al. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe. Genomics. 1994;22:288–95. [PubMed]
55. Neville LF, Gnatt A, Loewenstein Y, Soreq H. Aspartate-70 to glycine substitution confers resistance to naturally occurring and synthetic anionic-site ligands on in-ovo produced human butyrylcholinesterase. J Neurosci Res. 1990;27:452–60. [PubMed]
56. Johns T, Alonso JG. Glycoalkaloid change during domesticication of the potato, Solanum section petota. Euphytica. 1990;50:203–10.
57. Hawkes J. History of the potato. In: Harris PM, editor. The Potato Crop: The Scientific Basic for Improvement. London: Chapman & Hall; 1978. pp. 1–14.
58. Patinkin D, Seidman S, Eckstein F, Benseler F, Zakut H, Soreq H. Manipulations of cholinesterase gene expression modulate murine megakaryocytopoiesis in vitro. Mol Cell Biol. 1990;10:6046–50. [PMC free article] [PubMed]
59. Zakut H, Matzkel A, Schejter E, Avni A, Soreq H. Polymorphism of acetylcholinesterase in discrete regions of the developing human fetal brain. J Neurochem. 1985;45:382–9. [PubMed]
60. Lapidot-Lifson Y, Prody CA, Ginzberg D, Meytes D, Zakut H, Soreq H. Coamplification of human acetylcholinesterase and butyrylcholinesterase genes in blood cells: correlation with various leukemias and abnormal megakaryocytopoiesis. Proc Natl Acad Sci U S A. 1989;86:4715–9. [PubMed]
61. Zakut H, Ehrlich G, Ayalon A, et al. Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas. J Clin Invest. 1990;86:900–8. [PMC free article] [PubMed]
62. Prody CA, Dreyfus P, Zamir R, Zakut H, Soreq H. De novo amplification within a “silent” human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides. Proc Natl Acad Sci U S A. 1989;86:690–4. [PubMed]
63. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet. 1991;337:268–9. [PubMed]
64. Davies AMC, Blincow PJ. Glycoalkaloid content of potatoes and potato products sold in the U. K J Sci Food Agric. 1984;35:553–7.
65. Jones PG, Fenwick GR. The glycoalkaloid content of some edible solanaceous fruits and potato products. J Sci Food Agric. 1981;32:419–21. [PubMed]
66. Sizer CE, Maga JA, Craven CJ. Total glycoalkaloids in potatoes and potato chips. J Agric Food Chem. 1980;28:578–9. [PubMed]
67. Friedman M, Dao L. Distribution of glycoalkaloids in potato plants and commercial potato products. J Agric Food Chem. 1980;40:419–23.
68. Bushway RJ, Savage SA, Ferguson BS. Inhibition of acetylcholinesterase by solanaceous glycoalkaloids and alkaloids. Am Potato J. 1987;64:409–13.